NCT01405963View on ClinicalTrials.gov

Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

April 5, 2013

Study Completion Date

April 5, 2013

Conditions
Asthma
Interventions
DRUG

Placebo

Administered in a 1-hour intravenous infusion

BIOLOGICAL

Tezepelumab

Administered in a 1-hour intravenous infusion

Trial Locations (5)

T2N 4Z6

Research Site, Calgary

V5Z 1M9

Research Site, Vancouver

L8N 3Z5

Research Site, Hamilton

G1V 4G5

Research Site, Sainte-Foy

S7N 0W8

Research Site, Saskatoon

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01405963 - Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma | Biotech Hunter | Biotech Hunter